NASDAQ$STAA

STAAR Surgical Company · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

STAAR Surgical's performance was highlighted by record ICL sales and overall net sales growth, but profitability was impacted by increased operating expenses and adjustments related to the Other Products segment.

STAAR Surgical reported a 14% increase in net sales to $92.3 million, driven by a 19% increase in ICL sales. However, net income decreased to $6.1 million, or $0.12 per diluted share, due to higher operating expenses and accounting adjustments related to the Other Products segment. The company is updating its fiscal 2023 ICL sales outlook to a range of approximately $320 million to $325 million.

  • Net sales increased by 14% to $92.3 million, which includes a $0.7 million sales reduction related to Other Products.
  • ICL sales reached a record $93.1 million, representing a 19% year-over-year growth and a 20% growth in constant currency.
  • ICL unit sales increased by 21% year-over-year.
  • Net income was $0.12 per share, compared to $0.26 per share in the prior year quarter.

Headline financials

Total Revenue

$92.3M

Previous: $81.1M+13.8%
EPS (adj)

$0.40

Previous: $0.42-4.8%
Capital Expenditures

$3.01M

Previous: -$7.81M+138.6%
Free Cash Flow

-$9.32M

Previous: $5.23M-278.3%
Net Income

$6.06M

Previous: $13M-53.5%
Operating Income

$8.6M

Previous: $17M-49.5%
Gross Profit

$70.7M

Previous: $63.9M+10.7%
Cash & Equivalents

$94.7M

Previous: $202M-53.2%
Total Assets

$441M

Previous: $376M+17.2%
Stock-Based Comp

$8.42M

Previous: $5.75M+46.4%

Revenue & EPS history

STAAR Surgical · Revenue · Quarterly

$92.3M

Q2 2023+13.8%vs Q2 2022
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

Given increased conservatism related to the global environment, and a revised near-term outlook for U.S. growth, the company is updating its fiscal 2023 ICL sales outlook to a range of approximately $320 million to $325 million. At the mid-point of the range, our outlook represents approximately 20% growth over fiscal 2022 ICL sales of approximately $270 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+2.4%

Avg return

Earnings day

+1.9%

Avg return

5 days after

+3.5%

Avg return

30 days after

50%

30 / 60 earnings

Positive

+29.0%

Q1 2018

Best reaction

-24.7%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.3%+14.5%+0.6%
Q4 2025-1.4%-3.2%+6.8%
Q3 2025-0.3%-4.9%-0.2%
Q1 2025+0.2%-2.3%-8.1%
Q4 2024-24.7%-29.8%-22.1%
Q3 2024-4.3%-3.8%-3.9%
Q2 2024+6.5%+1.7%-17.9%
Q1 2024-10.8%-7.9%-12.0%
Q4 2023+6.6%+8.6%+22.9%
Q3 2023-13.9%-17.5%-21.1%
Q2 2023-10.5%-11.6%-18.4%
Q1 2023-5.8%-1.5%-15.9%
Q4 2022-12.7%-18.4%-9.6%
Q3 2022-18.9%-20.0%-14.1%
Q2 2022+23.1%+26.6%+16.8%
Q1 2022+1.9%-9.3%+7.6%
Q4 2021+13.1%+20.4%+10.7%
Q3 2021-1.5%-1.3%-24.8%
Q2 2021+21.3%+19.4%+22.4%
Q1 2021+8.6%-8.6%+12.6%
Q4 2020-4.3%-4.1%-9.7%
Q3 2020+2.4%+14.8%+7.0%
Q2 2020-6.8%-14.2%-16.7%
Q1 2020-0.5%+3.8%+14.8%
Q4 2019+2.0%+4.1%+1.9%
Q3 2019+14.6%+22.1%+28.8%
Q2 2019+14.9%+5.9%-0.6%
Q1 2019-13.3%-16.8%-28.7%
Q4 2018-0.6%-1.2%+2.7%
Q3 2018+10.6%+13.9%-1.2%
Q2 2018+25.6%+29.3%+54.6%
Q1 2018+29.0%+38.1%+84.8%
Q4 2017-9.1%-8.2%-7.2%
Q3 2017+12.0%+10.5%+17.0%
Q2 2017-1.4%-3.3%+11.6%
Q1 2017-2.9%-3.3%-10.0%
Q4 2016+1.5%-2.4%-4.4%
Q3 2016+9.8%+11.6%+28.0%
Q2 2016+19.9%+21.5%+30.4%
Q1 2016-22.4%
Q4 2015+17.1%
Q3 2015+13.0%
Q2 2015+1.2%
Q1 2015-6.0%
Q4 2013+10.1%
Q3 2013-3.6%
Q2 2013+18.6%
Q1 2013+20.8%
Q4 2012-5.6%
Q3 2012+7.5%
Q2 2012+26.3%
Q1 2011-10.1%
Q1 2012-0.7%
Q4 2011-0.8%
Q1 2009-0.8%
Q3 2010+7.7%
Q3 2011+7.7%
Q4 2010-6.7%
Q2 2010-6.7%
Q2 2011-6.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro